Seroma — Tranexamic Acid for Bleeding in Breast Surgery
Citation(s)
Alani HA, Balalaa N Complete tissue expander coverage by musculo-fascial flaps in immediate breast mound reconstruction after mastectomy. J Plast Surg Hand Surg. 2013 Oct;47(5):399-404. doi: 10.3109/2000656X.2013.772060. Epub 2013 Jun 26.
Carpelan A, Kauhanen S, Mattila K, Jahkola T, Tukiainen E Reduction mammaplasty as an outpatient procedure: a retrospective analysis of outcome and success rate. Scand J Surg. 2015 Jun;104(2):96-102. doi: 10.1177/1457496914526872. Epub 2014 May 7.
Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013 Jan;471(1):150-4. doi: 10.1007/s11999-012-2488-z.
Lapid O, Pietersen L, van der Horst CM Reoperation for haematoma after breast reduction with preoperative administration of low-molecular-weight heparin: experience in 720 patients. J Plast Reconstr Aesthet Surg. 2012 Nov;65(11):1513-7. doi: 10.1016/j.bjps.2012.05.027. Epub 2012 Jun 23.
Taylor JC, Rai S, Hoar F, Brown H, Vishwanath L Breast cancer surgery without suction drainage: the impact of adopting a 'no drains' policy on symptomatic seroma formation rates. Eur J Surg Oncol. 2013 Apr;39(4):334-8. doi: 10.1016/j.ejso.2012.12.022. Epub 2013 Feb 4.
Xu Q, Yang Y, Shi P, Zhou J, Dai W, Yao Z, Zhang C Repeated doses of intravenous tranexamic acid are effective and safe at reducing perioperative blood loss in total knee arthroplasty. Biosci Trends. 2014 Jun;8(3):169-75.
Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
